Apollomics (APLM) Non-Current Deffered Revenue (2023)
Apollomics' (APLM) quarterly Non-Current Deffered Revenue came in at -$2.8 million in Q4 2023, little changed quarter-over-quarter from -$2.8 million in Q2 2023.
Powered by 
Analysis
Apollomics (APLM) Non-Current Deffered Revenue (2023) Analysis & Trends
Apollomics (APLM) has reported Non-Current Deffered Revenue for 1 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2023.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to -$2.8 million in Q4 2023; TTM through Dec 2023 was -$2.8 million, a N/A change from a year earlier, with the FY2023 full-year figure at -$2.8 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was -$2.8 million for Q4 2023 at Apollomics, roughly flat from -$2.8 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at -$2.8 million in Q2 2023 and troughed at -$2.8 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | - |